Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2016

16.09.2015

Heparin: 100 years of pleiotropic effects

verfasst von: Adilson Ferraz Paschoa

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Heparin is a glycosaminoglycan with anticoagulant properties and antiinflammatory effects. The discovery of heparin approaches its 100th year and its antiinflammatory properties still draws much attention and anticipation to new possibilities of use and the likelihood of developing heparin-like drugs that lacked the anticoagulation effects. It is known that heparins limit the embolization and the extension of the thrombus, although they do not promote its complete lysis in most cases. The complexity and pleiotropic characteristics of these glycosaminoglycans still challenge science, to the point in which approaches hitherto unusual appear repeatedly in the literature. New indications, accompanied by longtime consecrated others, dismantle the idea of an outdated medication and create high expectations for the near future. The objective of this review is to analyze the pleiotropic effects of heparin and its use in several diseases, highlighting its safety and effectiveness.
Literatur
1.
Zurück zum Zitat Lever R, Mulloy B, Page C (2012) Heparin—a century of progress. Springer, BerlinCrossRef Lever R, Mulloy B, Page C (2012) Heparin—a century of progress. Springer, BerlinCrossRef
2.
Zurück zum Zitat Best CH (1959) Preparation of heparin and its use in the first clinical cases. Circulation 19(1):79–86CrossRefPubMed Best CH (1959) Preparation of heparin and its use in the first clinical cases. Circulation 19(1):79–86CrossRefPubMed
3.
Zurück zum Zitat Hirsh J, Siragusa S, Cosmi B, Ginsberg JS (1995) Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 74(1):360–363PubMed Hirsh J, Siragusa S, Cosmi B, Ginsberg JS (1995) Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 74(1):360–363PubMed
4.
Zurück zum Zitat Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P et al (1993) Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 153(13):1541–1546CrossRefPubMed Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P et al (1993) Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 153(13):1541–1546CrossRefPubMed
5.
Zurück zum Zitat Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l’Embolie Pulmonaire. N Engl J Med 337(10):663–669CrossRefPubMed Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l’Embolie Pulmonaire. N Engl J Med 337(10):663–669CrossRefPubMed
6.
Zurück zum Zitat ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 84(8):1099–1103CrossRef ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 84(8):1099–1103CrossRef
7.
Zurück zum Zitat Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D et al (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100(15):1593–1601CrossRefPubMed Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D et al (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100(15):1593–1601CrossRefPubMed
8.
Zurück zum Zitat Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354(14):1477–1488CrossRefPubMed Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354(14):1477–1488CrossRefPubMed
9.
Zurück zum Zitat Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337(7):447–452CrossRefPubMed Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337(7):447–452CrossRefPubMed
10.
Zurück zum Zitat Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J et al (2007) Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J 28(13):1566–1573CrossRefPubMed Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J et al (2007) Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J 28(13):1566–1573CrossRefPubMed
11.
Zurück zum Zitat Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW (2003) Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145(4):614–621CrossRefPubMed Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW (2003) Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145(4):614–621CrossRefPubMed
12.
Zurück zum Zitat Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al (1991) Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 114(7):545–551CrossRefPubMed Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al (1991) Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 114(7):545–551CrossRefPubMed
13.
Zurück zum Zitat Palmer AJ, Schramm W, Kirchhof B, Bergemann R (1997) Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Haemostasis 27(2):65–74PubMed Palmer AJ, Schramm W, Kirchhof B, Bergemann R (1997) Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Haemostasis 27(2):65–74PubMed
15.
Zurück zum Zitat Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S–e43SCrossRefPubMedPubMedCentral Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S–e43SCrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184SCrossRefPubMedPubMedCentral Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184SCrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162(16):1833–1840CrossRefPubMed Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162(16):1833–1840CrossRefPubMed
18.
Zurück zum Zitat Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494SCrossRefPubMedPubMedCentral Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494SCrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Ceccarelli M, Bani D, Cinci L, Nistri S, Uliva C, Ragazzo E et al (2009) Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med 13(8b):2704–2712CrossRefPubMed Ceccarelli M, Bani D, Cinci L, Nistri S, Uliva C, Ragazzo E et al (2009) Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med 13(8b):2704–2712CrossRefPubMed
20.
Zurück zum Zitat Young E (2008) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122(6):743–752CrossRefPubMed Young E (2008) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122(6):743–752CrossRefPubMed
21.
Zurück zum Zitat Bono F, Rigon P, Lamarche I, Savi P, Salel V, Herbert JM (1997) Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells. Biochem J 326(Pt 3):661–668CrossRefPubMedPubMedCentral Bono F, Rigon P, Lamarche I, Savi P, Salel V, Herbert JM (1997) Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells. Biochem J 326(Pt 3):661–668CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Fredens K, Dahl R, Venge P (1991) In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy 46(1):27–29CrossRefPubMed Fredens K, Dahl R, Venge P (1991) In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy 46(1):27–29CrossRefPubMed
23.
Zurück zum Zitat Gilat D, Hershkoviz R, Mekori YA, Vlodavsky I, Lider O (1994) Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol. 153(11):4899–4906PubMed Gilat D, Hershkoviz R, Mekori YA, Vlodavsky I, Lider O (1994) Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol. 153(11):4899–4906PubMed
24.
Zurück zum Zitat Page CP (1991) One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 337(8743):717–720CrossRefPubMed Page CP (1991) One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 337(8743):717–720CrossRefPubMed
25.
Zurück zum Zitat Walsh RL, Dillon TJ, Scicchitano R, McLennan G (1991) Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci (Lond). 81(3):341–346CrossRefPubMed Walsh RL, Dillon TJ, Scicchitano R, McLennan G (1991) Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci (Lond). 81(3):341–346CrossRefPubMed
26.
Zurück zum Zitat Brown RA, Allegra L, Matera MG, Page CP, Cazzola M (2006) Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 19(6):419–424CrossRefPubMed Brown RA, Allegra L, Matera MG, Page CP, Cazzola M (2006) Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 19(6):419–424CrossRefPubMed
27.
Zurück zum Zitat Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE (2005) Regulation of protein function by glycosaminoglycans—as exemplified by chemokines. Annu Rev Biochem 74:385–410CrossRefPubMed Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE (2005) Regulation of protein function by glycosaminoglycans—as exemplified by chemokines. Annu Rev Biochem 74:385–410CrossRefPubMed
28.
Zurück zum Zitat Lever R, Lo WT, Faraidoun M, Amin V, Brown RA, Gallagher J et al (2007) Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 151(6):837–843CrossRefPubMedPubMedCentral Lever R, Lo WT, Faraidoun M, Amin V, Brown RA, Gallagher J et al (2007) Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 151(6):837–843CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P et al (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173(9):5776–5785CrossRefPubMed Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P et al (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173(9):5776–5785CrossRefPubMed
31.
Zurück zum Zitat de Boer JD, Majoor CJ, van t Veer C, Bel EHD, van der Poll T (2012) Asthma and coagulation. Blood 119(14):3236–3244CrossRefPubMed de Boer JD, Majoor CJ, van t Veer C, Bel EHD, van der Poll T (2012) Asthma and coagulation. Blood 119(14):3236–3244CrossRefPubMed
32.
Zurück zum Zitat Duong M, Cockcroft D, Boulet LP, Ahmed T, Iverson H, Atkinson DC et al (2008) The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma. Allergy 63(9):1195–1201CrossRefPubMed Duong M, Cockcroft D, Boulet LP, Ahmed T, Iverson H, Atkinson DC et al (2008) The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma. Allergy 63(9):1195–1201CrossRefPubMed
33.
Zurück zum Zitat Stelmach I, Jerzynska J, Stelmach W, Majak P, Brzozowska A, Gorski P et al (2003) The effect of inhaled heparin on airway responsiveness to histamine and leukotriene D4. Allergy Asthma Proc 24(1):59–65PubMed Stelmach I, Jerzynska J, Stelmach W, Majak P, Brzozowska A, Gorski P et al (2003) The effect of inhaled heparin on airway responsiveness to histamine and leukotriene D4. Allergy Asthma Proc 24(1):59–65PubMed
34.
Zurück zum Zitat Passowicz-Muszynska E, Jankowska R, Krasnowska M (2002) The effect of inhaled low molecular weight heparin on cell composition in bronchoalveolar lavage fluid and serum levels of soluble receptor IL-2 in bronchial asthma patients. Pol Merkur Lekarski 12(69):218–220PubMed Passowicz-Muszynska E, Jankowska R, Krasnowska M (2002) The effect of inhaled low molecular weight heparin on cell composition in bronchoalveolar lavage fluid and serum levels of soluble receptor IL-2 in bronchial asthma patients. Pol Merkur Lekarski 12(69):218–220PubMed
35.
Zurück zum Zitat Fal AM, Miecielica J, Krasnowska M, Medrala W, Kuryszko J, Malolepszy J (2001) Influence of long-term low molecular weight heparin nebulization on selected clinical parameters and course of allergic inflammation in patients with bronchial asthma. Pol Arch Med Wewn 106(6):1121–1129PubMed Fal AM, Miecielica J, Krasnowska M, Medrala W, Kuryszko J, Malolepszy J (2001) Influence of long-term low molecular weight heparin nebulization on selected clinical parameters and course of allergic inflammation in patients with bronchial asthma. Pol Arch Med Wewn 106(6):1121–1129PubMed
36.
Zurück zum Zitat Tutluoglu B, Gurbuz N, Atis S, Abanozlu S, Ibis R, Kanik A (2001) Effects of heparin on hypertonic potassium chloride-induced bronchoconstriction. Ann Pharmacother 35(10):1161–1165CrossRefPubMed Tutluoglu B, Gurbuz N, Atis S, Abanozlu S, Ibis R, Kanik A (2001) Effects of heparin on hypertonic potassium chloride-induced bronchoconstriction. Ann Pharmacother 35(10):1161–1165CrossRefPubMed
37.
Zurück zum Zitat Vancheri C, Mastruzzo C, Armato F, Tomaselli V, Magri S, Pistorio MP et al (2001) Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 108(5):703–708CrossRefPubMed Vancheri C, Mastruzzo C, Armato F, Tomaselli V, Magri S, Pistorio MP et al (2001) Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 108(5):703–708CrossRefPubMed
38.
Zurück zum Zitat Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H et al (2012) Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS ONE 7(6):e38629CrossRefPubMedPubMedCentral Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H et al (2012) Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS ONE 7(6):e38629CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Qian Y, Xie H, Tian R, Yu K, Wang R (2014) Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Copd. 11(2):171–176CrossRefPubMed Qian Y, Xie H, Tian R, Yu K, Wang R (2014) Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Copd. 11(2):171–176CrossRefPubMed
40.
Zurück zum Zitat Shi X, Li H (2013) Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage. Exp Ther Med 5(5):1367–1370PubMedPubMedCentral Shi X, Li H (2013) Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage. Exp Ther Med 5(5):1367–1370PubMedPubMedCentral
41.
Zurück zum Zitat Falanga A (2004) The effect of anticoagulant drugs on cancer. J Thromb Haemost 2(8):1263–1265CrossRefPubMed Falanga A (2004) The effect of anticoagulant drugs on cancer. J Thromb Haemost 2(8):1263–1265CrossRefPubMed
42.
Zurück zum Zitat Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275CrossRefPubMedPubMedCentral Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Khorana AA (2012) Cancer-associated thrombosis: updates and controversies. Hematol Am Soc Hematol Educ Program 2012:626–630 Khorana AA (2012) Cancer-associated thrombosis: updates and controversies. Hematol Am Soc Hematol Educ Program 2012:626–630
44.
Zurück zum Zitat Lee AY (2012) Treatment of established thrombotic events in patients with cancer. Thromb Res 129(Suppl 1):S146–S153CrossRefPubMed Lee AY (2012) Treatment of established thrombotic events in patients with cancer. Thromb Res 129(Suppl 1):S146–S153CrossRefPubMed
45.
Zurück zum Zitat Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6):vi85–vi92PubMed Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6):vi85–vi92PubMed
46.
Zurück zum Zitat Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C et al (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 74(1):38–45CrossRefPubMed Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C et al (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 74(1):38–45CrossRefPubMed
47.
Zurück zum Zitat Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR (1999) The effects of unfractionated heparin on survival in patients with malignancy—a systematic review. Thromb Haemost 82(6):1600–1604PubMed Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR (1999) The effects of unfractionated heparin on survival in patients with malignancy—a systematic review. Thromb Haemost 82(6):1600–1604PubMed
48.
Zurück zum Zitat Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR (2001) The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86(6):1586–1587PubMed Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR (2001) The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86(6):1586–1587PubMed
49.
Zurück zum Zitat von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L (2000) Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16(4):815–824 von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L (2000) Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16(4):815–824
50.
Zurück zum Zitat Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ et al (1981) Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 245(8):831–835CrossRefPubMed Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ et al (1981) Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 245(8):831–835CrossRefPubMed
51.
Zurück zum Zitat Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82(2):947–952PubMed Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82(2):947–952PubMed
52.
Zurück zum Zitat Zhang J, Zhang YL, Ma KX, Qu JM (2013) Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax 68(5):442–450CrossRefPubMed Zhang J, Zhang YL, Ma KX, Qu JM (2013) Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax 68(5):442–450CrossRefPubMed
53.
Zurück zum Zitat Che DH, Cao JY, Shang LH, Man YC, Yu Y (2013) The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med 24(5):433–439CrossRefPubMed Che DH, Cao JY, Shang LH, Man YC, Yu Y (2013) The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med 24(5):433–439CrossRefPubMed
54.
Zurück zum Zitat Lecumberri R, Lopez Vivanco G, Font A, Gonzalez Billalabeitia E, Gurpide A, Gomez Codina J et al (2013) Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res 132(6):666–670CrossRefPubMed Lecumberri R, Lopez Vivanco G, Font A, Gonzalez Billalabeitia E, Gurpide A, Gomez Codina J et al (2013) Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res 132(6):666–670CrossRefPubMed
55.
Zurück zum Zitat van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR (2011) Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 29(15):2071–2076CrossRefPubMed van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR (2011) Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 29(15):2071–2076CrossRefPubMed
56.
Zurück zum Zitat Kahn SR (2006) The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 21(1):41–48CrossRefPubMed Kahn SR (2006) The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 21(1):41–48CrossRefPubMed
57.
Zurück zum Zitat Roberts LN, Patel RK, Donaldson N, Bonner L, Arya R (2014) Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. Haematologica 99(3):e41–e43CrossRefPubMedPubMedCentral Roberts LN, Patel RK, Donaldson N, Bonner L, Arya R (2014) Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. Haematologica 99(3):e41–e43CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S et al (2009) Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 122(8):762–769CrossRefPubMed Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S et al (2009) Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 122(8):762–769CrossRefPubMed
59.
Zurück zum Zitat Gonzalez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C (2008) Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: comparative study of enoxaparin versus coumarin. J Vasc Surg 48(4):953–959CrossRefPubMed Gonzalez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C (2008) Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: comparative study of enoxaparin versus coumarin. J Vasc Surg 48(4):953–959CrossRefPubMed
60.
Zurück zum Zitat Hull RD, Liang J, Townshend G (2011) Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 124(8):756–765CrossRefPubMed Hull RD, Liang J, Townshend G (2011) Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 124(8):756–765CrossRefPubMed
61.
Zurück zum Zitat Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S et al (2013) Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 11(2):270–281CrossRefPubMed Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S et al (2013) Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 11(2):270–281CrossRefPubMed
62.
Zurück zum Zitat Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P (2014) Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2:Cd001689PubMed Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P (2014) Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2:Cd001689PubMed
63.
Zurück zum Zitat Middeldorp S (2013) Thrombosis in women: what are the knowledge gaps in 2013? J Thromb Haemost 11(Suppl 1):180–191CrossRefPubMed Middeldorp S (2013) Thrombosis in women: what are the knowledge gaps in 2013? J Thromb Haemost 11(Suppl 1):180–191CrossRefPubMed
65.
Zurück zum Zitat Sanford D, Naidu A, Alizadeh N, Lazo-Langner A (2014) The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost 12(7):1076–1085CrossRefPubMed Sanford D, Naidu A, Alizadeh N, Lazo-Langner A (2014) The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost 12(7):1076–1085CrossRefPubMed
66.
Zurück zum Zitat Lazo-Langner A, Goss GD, Spaans JN, Rodger MA (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5(4):729–737CrossRefPubMed Lazo-Langner A, Goss GD, Spaans JN, Rodger MA (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5(4):729–737CrossRefPubMed
Metadaten
Titel
Heparin: 100 years of pleiotropic effects
verfasst von
Adilson Ferraz Paschoa
Publikationsdatum
16.09.2015
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1261-z

Weitere Artikel der Ausgabe 4/2016

Journal of Thrombosis and Thrombolysis 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.